, Volume 79, Issue 16, pp 1805–1812 | Cite as

Pexidartinib: First Approval

  • Yvette N. LambEmail author
AdisInsight Report


Pexidartinib (TURALIO™) is an orally administered small molecule tyrosine kinase inhibitor with selective activity against the colony-stimulating factor 1 (CSF1) receptor, KIT proto-oncogene receptor tyrosine kinase (KIT) and FMS-like tyrosine kinase 3 harboring an internal tandem duplication mutation (FLT3-ITD). In August 2019, the US FDA approved pexidartinib capsules for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations and not amenable to improvement with surgery. This approval was based on positive results from the phase III ENLIVEN trial. Pexidartinib is being investigated in various malignancies as monotherapy or combination therapy. This article summarizes the milestones in the development of pexidartinib leading to its first approval for TGCT.


Compliance with Ethical Standards


The preparation of this review was not supported by any external funding.

Conflicts of interest

During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the author on the basis of scientific completeness and accuracy. Yvette Lamb is a salaried employee of Adis International Ltd/Springer Nature, is responsible for the article content and declares no relevant conflicts of interest.


  1. 1.
    Ao JY, Zhu XD, Chai ZT, et al. Colony-stimulating factor 1 receptor blockade inhibits tumor growth by altering the polarization of tumor-associated macrophages in hepatocellular carcinoma. Mol Cancer Ther. 2017;16(8):1544–54.CrossRefGoogle Scholar
  2. 2.
    DeNardo DG, Brennan DJ, Rexhepaj E, et al. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov. 2011;1(1):54–67.CrossRefGoogle Scholar
  3. 3.
    Tap WD, Wainberg ZA, Anthony SP, et al. Structure-guided blockade of CSF1R kinase in tenosynovial giant-cell tumor. N Engl J Med. 2015;373(5):428–37.CrossRefGoogle Scholar
  4. 4.
    Shi G, Yang Q, Zhang Y, et al. Modulating the tumor microenvironment via oncolytic viruses and CSF-1R inhibition synergistically enhances anti-PD-1 immunotherapy. Mol Ther. 2019;27(1):244–60.CrossRefGoogle Scholar
  5. 5.
    Stafford JH, Hirai T, Deng L, et al. Colony stimulating factor 1 receptor inhibition delays recurrence of glioblastoma after radiation by altering myeloid cell recruitment and polarization. Neuro Oncol. 2016;18(6):797–806.CrossRefGoogle Scholar
  6. 6.
    Wesolowski R, Sharma N, Reebel L, et al. Phase Ib study of the combination of pexidartinib (PLX3397), a CSF-1R inhibitor, and paclitaxel in patients with advanced solid tumors. Ther Adv Med Oncol. 2019;11:1–13.CrossRefGoogle Scholar
  7. 7.
    Burton E, Wong B, Zhang J. The novel inhibitor PLX3397 effectively inhibits FLT3-mutant AML. Blood. 2011;118:3632.CrossRefGoogle Scholar
  8. 8.
    Smith CC, Zhang C, Lin KC, et al. Characterizing and overriding the structural mechanism of the quizartinib-resistant FLT3 “gatekeeper” F691L mutation with PLX3397. Cancer Discov. 2015;5(6):668–79.CrossRefGoogle Scholar
  9. 9.
    Daiichi Sankyo Inc. TURALIOTM (pexidartinib) capsules, for oral use: US prescribing information 2019. Accessed 30 Sep 2019.
  10. 10.
    Gelhorn HL, Tong S, McQuarrie K, et al. Patient-reported symptoms of tenosynovial giant cell tumors. Clin Ther. 2016;38(4):778–93.CrossRefGoogle Scholar
  11. 11.
    Giustini N, Bernthal NM, Bukata SV, et al. Tenosynovial giant cell tumor: case report of a patient effectively treated with pexidartinib (PLX3397) and review of the literature. Clin Sarcoma Res. 2018;8:14.CrossRefGoogle Scholar
  12. 12.
    Food and Drug Administration. FDA approves first therapy for rare joint tumor [media release]. 2 Aug 2019.
  13. 13.
    Tap WD, Gelderblom H, Palmerini E, et al. Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial. Lancet. 2019;394(10197):478–87.CrossRefGoogle Scholar
  14. 14.
    Yan D, Kowal J, Akkari L, et al. Inhibition of colony stimulating factor-1 receptor abrogates microenvironment-mediated therapeutic resistance in gliomas. Oncogene. 2017;36(43):6049–58.CrossRefGoogle Scholar
  15. 15.
    Patwardhan PP, Surriga O, Beckman MJ, et al. Sustained inhibition of receptor tyrosine kinases and macrophage depletion by PLX3397 and rapamycin as a potential new approach for the treatment of MPNSTs. Clin Cancer Res. 2014;20(12):3146–58.CrossRefGoogle Scholar
  16. 16.
    Mok S, Koya RC, Tsui C, et al. Inhibition of CSF-1 receptor improves the antitumor efficacy of adoptive cell transfer immunotherapy. Cancer Res. 2014;74(1):153–61.CrossRefGoogle Scholar
  17. 17.
    Vandell AG, Duchin KL, Desai M, et al. Effect of dose strength, food, and pH modifiers on the pharmacokinetics of the multi-kinase inhibitor pexidartinib [abstract no. PI-152]. Clin Pharmacol Ther. 2018;103(Suppl S1):S54.Google Scholar
  18. 18.
    Daiichi Sankyo Inc. Briefing document for the May 14, 2019, US FDA oncologic drugs advisory committee meeting: Turalio (pexidartinib) capsules. 2019. Accessed 30 Sep 2019.
  19. 19.
    Gelderblom H, Tap WD, Palmerini E, et al. Pexidartinib for advanced tenosynovial giant cell tumor (TGCT): long-term efficacy and safety from the phase 3 ENLIVEN and phase 1 PLX108-01 (TGCT cohort) studies [abstract no. 11042]. J Clin Oncol. 2019;37(Suppl 15):11042.Google Scholar
  20. 20.
    Butowski N, Colman H, De Groot JF, et al. Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study. Neuro Oncol. 2016;18(4):557–64.CrossRefGoogle Scholar
  21. 21.
    Colman H, Raizer JJ, Walbert T, et al. Phase 1b/2 study of pexidartinib (PEX) in combination with radiation therapy (XRT) and temozolomide (TMZ) in newly diagnosed glioblastoma [abstract no. 2015]. J Clin Oncol. 2018;36(Suppl 15):2015.CrossRefGoogle Scholar
  22. 22.
    Manji GA, Van Tine BA, Lee SM, et al. Phase 1 combination therapy with pexidartinib (PEX) and sirolimus (S) to target tumor-associated macrophages in pigmented villonodular synovitis, malignant peripheral nerve sheath tumors, and other soft tissue sarcomas [abstract no. 11055]. J Clin Oncol. 2019;37(Suppl 15):11055.Google Scholar
  23. 23.
    Rosenbaum E, Kelly C, D’Angelo SP, et al. A phase I study of binimetinib (MEK162) combined with pexidartinib (PLX3397) in patients with advanced gastrointestinal stromal tumor. Oncologist. 2019;24:1–8.CrossRefGoogle Scholar
  24. 24.
    Wagner AJ, Tap WD, Shields AF, et al. A phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of PLX9486 alone and in combination (combo) with the KIT inhibitors pexidartinib (pexi) or sunitinib (su) in patients (Pts) with advanced solid tumors and gastrointestinal stromal tumor (GIST) [abstract no. 11509]. J Clin Oncol. 2018;36(Suppl 15):11509.CrossRefGoogle Scholar
  25. 25.
    Cassier PA, Garin G, Eberst L, et al. MEDIPLEX: a phase 1 study of durvalumab (D) combined with pexidartinib (P) in patients (pts) with advanced pancreatic ductal adenocarcinoma (PDAC) and colorectal cancer (CRC) [abstract no. 2579]. J Clin Oncol. 2019;37(Suppl 15):2579.CrossRefGoogle Scholar
  26. 26.
    Hittson L, Glod J, Amaya M, et al. Phase I study of pexidartinib (PLX3397) in children with refractory leukemias and solid tumors including neurofibromatosis type I (NF1) related plexiform neurofibromas (PN) [abstract no. 10546]. J Clin Oncol. 2017;35(Suppl 15):10546.CrossRefGoogle Scholar
  27. 27.
    Lee JH, Chen TW, Hsu CH, et al. A phase I study of pexidartinib, a colony-stimulating factor 1 receptor inhibitor, in Asian patients with advanced solid tumors. Invest New Drugs. 2019. Scholar
  28. 28.
    Daiichi Sankyo Company. ENLIVEN phase 3 study of pexidartinib in tenosynovial giant cell tumor (TGCT) will continue to completion following enrollment discontinuation [media release]. 21 Oct 2016.
  29. 29.
    Bauer S, Lewis JH, Gelderblom H, et al. Pexidartinib for locally advanced tenosynovial giant cell tumor (TGCT): characterization of hepatic adverse reactions (ARs) [poster no. 1696P]. In: ESMO 2019.Google Scholar
  30. 30.
    Mastboom M, Palmerini E, Stacchiotti S, et al. First prospective observational study in diffuse-type tenosynovial giant cell tumors [abstract no. 11560]. J Clin Oncol. 2018;36(Suppl 15):11560.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Springer NatureAucklandNew Zealand

Personalised recommendations